In conclusion, higher TILs and PD-L1+TILs in pre-NAT specimens may also forecast the effectiveness of neoadjuvant trastuzumab with chemotherapy for HER2-positive breast cancer, in accordance with our findings. The gene discussed is ERBB2; the disease is breast cancer.